发明名称 TUMOR SPECIFIC T-CELL RECEPTORS
摘要 The present invention relates to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids encoding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as their use is the treatment of tumorous diseases.
申请公布号 US2015307585(A1) 申请公布日期 2015.10.29
申请号 US201314648314 申请日期 2013.11.29
申请人 MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCH 发明人 BLANKENSTEIN Thomas;WILLIMSKY Gerald
分类号 C07K14/725 主分类号 C07K14/725
代理机构 代理人
主权项 1. A method for the production of a human T cell receptor (TCR) that is specific for tumorous cells and has reduced adverse effects in adoptive T-cell therapy, wherein said method comprises: providing a host organism expressing unrearranged human TCR loci, b. immunizing said host organism with a peptide comprising an epitope specific for a tumor specific antigen (TSA), isolating from said host organism a T cell clone having an activity against said human-mutated TSA, and d. optionally, isolating from said T cell clone the TCR, wherein said TSA is selected out of the class of somatic mutated antigens.
地址 Berlin DE